Table 1.

Frequencies of HLA-B and HLA-DRB1 were determined for HFRS patients and the control group and compared among groups of patients and/or the control group^a

Allele	Frequency (%) among individuals in indicated group				P value (relative risk)b
	Control (n = 131)	HFRS (n = 160)	DOBV (n = 72)	PUUV (n = 88)	HFRS/control	DOBV/control	PUUV/control	DOBV/PUUV
B*07	24.4	18.1	19.4	18.4	NS	NS	NS	NS
B*08	13.7	11.3	11.9	11.5	NS	NS	NS	NS
B*13	6.9	8.1	6.0	10.3	NS	NS	NS	NS
B*14	3.1	5.6	7.5	4.6	NS	NS	NS	NS
B*15	7.6	8.8	6.0	11.5	NS	NS	NS	NS
B*18	16.0	12.5	9.0	16.1	NS	NS	NS	NS
B*27	13.0	18.8	19.4	19.5	NS	NS	NS	NS
B*35	23.7	24.4	34.3	18.4	NS	NS	NS	0.027
B*37	3.1	0.6	0.0	1.2	NS	NS	NS	NS
B*38	8.4	8.1	7.5	9.2	NS	NS	NS	NS
B*39	3.1	3.1	4.5	2.3	NS	NS	NS	NS
B*40	9.9	8.1	6.0	10.3	NS	NS	NS	NS
B*41	1.5	1.9	1.5	2.3	NS	NS	NS	NS
B*44	17.6	17.5	23.9	13.8	NS	NS	NS	NS
B*47	0.0	1.3	1.5	1.2	NS	NS	NS	NS
B*49	4.6	3.1	3.0	3.5	NS	NS	NS	NS
B*50	3.1	2.5	4.5	1.2	NS	NS	NS	NS
B*51	13.0	17.5	16.4	19.5	NS	NS	NS	NS
B*52	2.3	1.3	0.0	2.3	NS	NS	NS	NS
B*53	3.1	0.0	0.0	0.0	0.040 (0.0)	NS	NS	NS
B*55	4.6	4.4	4.5	4.6	NS	NS	NS	NS
B*56	0.8	1.9	0.0	3.5	NS	NS	NS	NS
B*57	6.9	6.9	6.0	8.1	NS	NS	NS	NS
B*58	3.1	0.6	0.0	1.2	NS	NS	NS	NS
DRB1*01	28.2	29.4	33.8	26.1	NS	NS	NS	NS
DRB1*03	23.7	14.4	16.9	12.5	0.049 (0.737)	NS	0.053* (0.602)	NS
DRB1*04	16.0	17.5	18.3	17.1	NS	NS	NS	NS
DRB1*07	18.3	22.5	22.5	22.7	NS	NS	NS	NS
DRB1*08	3.1	5.0	5.6	4.6	NS	NS	NS	NS
DRB1*10	0.8	1.3	0.0	2.3	NS	NS	NS	NS
DRB1*11	26.0	25.6	23.9	27.3	NS	NS	NS	NS
DRB1*12	0.8	2.5	4.2	1.1	NS	NS	NS	NS
DRB1*13	20.6	25.6	18.3	31.8	NS	NS	0.080* (1.392)	0.068*
DRB1*14	8.4	8.8	12.7	5.7	NS	NS	NS	NS
DRB1*15	22.1	19.4	16.9	21.6	NS	NS	NS	NS
DRB1*16	16.0	10.6	9.9	11.4	NS	NS	NS	NS

^aThe groups comprised a control group of healthy individuals and a group of HFRS patients which was additionally separated into a DOBV-infected group and a PUUV-infected group.

^bP values between indicated groups were determined using the two-tailed Fischer's exact test. NS, not significant; *, borderline significant (P < 0.1).